APAC IPOs & Placements, Aequitas Research

Kajal Jain

At Aequitas we cover all IPOs and placements across Asia-Pac with a deal size of at least US$100m. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

APAC IPOs & Placements

Integris Medtech Limited Pre-IPO Tearsheet

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Integris Medtech Limited / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/integris-medtech-limited" target="_blank" data-smartkarma-citation="entities:45943:1" rel="noopener">Integris Medtech Limited (1234518D IN)</a> (IML) plans to raise around US$340m in its upcoming IPO.</li>
<li>IML is a diversified India-based global MedTech company engaged in the development, manufacturing, and commercialization of medical devices and laboratory solutions.</li>
<li>In this note, we talk about the company's historical performance.</li>
</ul>



Integris Medtech Limited (1234518D IN) (IML) plans to raise around US$340m in its upcoming IPO.
IML is a diversified India-based global MedTech company engaged in the development, manufacturing, and commercialization of medical devices and laboratory solutions.
In this note, we talk about the company's historical performance.


Aequitas：Integris Medtech Ltd（IPO前）：力強い成長が見込まれるものの、レバレッジが高い医療技術プラットフォーム